OTCMKTS:NEVPF - NeuroVive Pharmaceutical Stock Price, News, & Analysis

$0.1519
+0.00 (+2.08 %)
(As of 06/18/2019 04:00 PM ET)
Today's Range
$0.1519
Now: $0.1519
$0.1519
50-Day Range
$0.0988
MA: $0.14
$0.1536
52-Week Range
$0.0988
Now: $0.1519
$0.6688
Volume200 shs
Average Volume9,332 shs
Market Capitalization$7.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases. The company also develops NVP015/NV354 drug candidates for mitochondrial diseases; NVP025 drug candidate for mitochondrial myopathies; NV556 and NVP022 drug candidates for non-alcoholic steatohepatitis conditions; and NVP024, a hepatocellular carcinoma program. NeuroVive Pharmaceutical AB (publ) has collaboration agreements with Isomerase Therapeutics, Sihuan Pharmaceutical, and Sanofi Korea. The company also has a preclinical collaboration agreement with the Children's Hospital of Philadelphia for research in genetic mitochondrial disorders. NeuroVive Pharmaceutical AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NEVPF
CUSIPN/A
CIKN/A
Phone46-4-627-562-20

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.21 per share

Profitability

Net Income$-7,870,000.00

Miscellaneous

Employees7
Market Cap$7.95 million
Next Earnings Date6/18/2019 (Estimated)
OptionableNot Optionable

Receive NEVPF News and Ratings via Email

Sign-up to receive the latest news and ratings for NEVPF and its competitors with MarketBeat's FREE daily newsletter.

NeuroVive Pharmaceutical (OTCMKTS:NEVPF) Frequently Asked Questions

What is NeuroVive Pharmaceutical's stock symbol?

NeuroVive Pharmaceutical trades on the OTCMKTS under the ticker symbol "NEVPF."

How were NeuroVive Pharmaceutical's earnings last quarter?

NeuroVive Pharmaceutical AB (OTCMKTS:NEVPF) released its earnings results on Monday, March, 25th. The company reported ($0.02) earnings per share for the quarter. View NeuroVive Pharmaceutical's Earnings History.

When is NeuroVive Pharmaceutical's next earnings date?

NeuroVive Pharmaceutical is scheduled to release their next quarterly earnings announcement on Tuesday, June 18th 2019. View Earnings Estimates for NeuroVive Pharmaceutical.

Has NeuroVive Pharmaceutical been receiving favorable news coverage?

Media stories about NEVPF stock have trended positive recently, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. NeuroVive Pharmaceutical earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for NeuroVive Pharmaceutical.

Who are some of NeuroVive Pharmaceutical's key competitors?

What other stocks do shareholders of NeuroVive Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroVive Pharmaceutical investors own include Allena Pharmaceuticals (ALNA), Okta (OKTA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP), Ardelyx (ARDX) and ArQule (ARQL).

Who are NeuroVive Pharmaceutical's key executives?

NeuroVive Pharmaceutical's management team includes the folowing people:
  • Mr. Erik Kinnmann M.D., Ph.D., M.B.A., Assoc. Prof., Chief Exec. Officer (Age 61)
  • Ms. Catharina Jz Johansson, CFO & VP of Investor Relations (Age 52)
  • Dr. Eskil Elmér, Chief Scientific Officer & VP of Discovery (Age 49)
  • Daniel Schale, Director of Communications
  • Dr. Magnus Hansson, Chief Medical Officer and VP of Preclinical & Clinical Devel. (Age 43)

How do I buy shares of NeuroVive Pharmaceutical?

Shares of NEVPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NeuroVive Pharmaceutical's stock price today?

One share of NEVPF stock can currently be purchased for approximately $0.1519.

How big of a company is NeuroVive Pharmaceutical?

NeuroVive Pharmaceutical has a market capitalization of $7.95 million. The company earns $-7,870,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. NeuroVive Pharmaceutical employs 7 workers across the globe.View Additional Information About NeuroVive Pharmaceutical.

What is NeuroVive Pharmaceutical's official website?

The official website for NeuroVive Pharmaceutical is http://www.neurovive.com/.

How can I contact NeuroVive Pharmaceutical?

NeuroVive Pharmaceutical's mailing address is MEDICON VILLAGE SCHEELEVAGEN 2, LUND V7, 223 81. The company can be reached via phone at 46-4-627-562-20 or via email at [email protected]


MarketBeat Community Rating for NeuroVive Pharmaceutical (OTCMKTS NEVPF)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  55 (Thanks for Voting!)
Underperform Votes:  55 (Thanks for Voting!)
Total Votes:  110
MarketBeat's community ratings are surveys of what our community members think about NeuroVive Pharmaceutical and other stocks. Vote "Outperform" if you believe NEVPF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEVPF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2019 by MarketBeat.com Staff

Featured Article: Hold Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel